Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning

Campbell, Belinda A.; Callahan, Jason; Bressel, Mathias; Simoens, Nathalie; Everitt, Sarah; Hofman, Michael S; Hicks, Rodney J.; Burbury, Kate; MacManus, Michael

doi:10.1016/j.ijrobp.2015.04.027

Cited by 36 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 When contrasting the results from the study using nuclear medicine data to the distribution of DTC bone metastases from our systematic review, it is evident that the relative distribution of bone metastases and red marrow content follow a similar rank ( Table 6). 32 Our compilation of literature series revealed that the 55.5% of bone metastases originate from FTCs and 31.5% originate from papillary thyroid carcinomas, which is in accordance with this hypothesis. 32 This anatomic diagram largely correlates with the distribution of DTC bone metastases from our literature review, however, this study has isolated the sternum and grouped the ribs, clavicle, and scapulae in 1 category, whereas we have grouped the sternum and ribs, and the clavicle and scapulae, as 2 separate categories.…”

Section: Discussionsupporting

confidence: 76%

“…30 These results confirmed previous reports in the literature from cadaveric studies. 32 This anatomic diagram largely correlates with the distribution of DTC bone metastases from our literature review, however, this study has isolated the sternum and grouped the ribs, clavicle, and scapulae in 1 category, whereas we have grouped the sternum and ribs, and the clavicle and scapulae, as 2 separate categories. [8][9][10][11][12][13][14][15][16][17][18][19][20]30 A 2015 study furthermore produced a color-coded atlas of the proportional distribution of functional bone marrow in adult patients with cancer.…”

Section: Discussionmentioning

confidence: 63%

See 1 more Smart Citation

Systematic review of site distribution of bone metastases in differentiated thyroid cancer

Osorio

Moubayed

et al. 2017

Head Neck

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 63%

Systematic review of site distribution of bone metastases in differentiated thyroid cancer

Osorio

Moubayed

et al. 2017

Head Neck

View full text Add to dashboard Cite

show abstract

“…The distal half of the femur and humerus were also excluded from BM because they contain little proliferating bone marrow. 24 The absolute volumes of the three organs at risk receiving 5-, 10-, 20-, and 30 Gy (V5, V10, V20, and V30) were recorded.…”

Section: Methodsmentioning

confidence: 99%

Dosimetric predictors of treatment-related lymphopenia induced by palliative radiotherapy: predictive ability of dose-volume parameters based on body surface contour

Saitô

Toya

Matsuyama

et al. 2016

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundRadiation-related lymphopenia has been associated with poor patient outcome. Our aim was to identify predictors of lymphopenia after palliative radiotherapy, with a focus on dose-volume parameters.Patients and methodsTo retrospectively assess patients with various cancers who had undergone palliative radiotherapy, we delineated three organs at risk: the volume enclosed by the body surface contour (body A), the volume left after excluding air, pleural effusion, ascites, bile, urine, and intestinal content (body B), and the volume of the bone marrow (BM). We then noted the absolute volume of the three organs at risk that had received 5-30 Gy, and assessed the predictive value for post-treatment lymphopenia of grade 3 or higher (LP3+).ResultsOf 54 patients, 23 (43%) developed LP3+. Univariate logistic regression analysis showed that body A V5, body A V10, body B V5, body B V10, the number of fractions, and splenic irradiation were significant predictors of LP3+ (p < 0.05). By multivariate analysis, body A V5, body A V10, body B V5, body B V10, and the number of fractions retained significance (p < 0.05). BM dose-volume parameters did not predict lymphopenia.ConclusionsHigher body A and body B dose-volume parameters and a larger number of fractions may be predictors of severe lymphopenia after palliative radiotherapy.

show abstract

“…On the whole, our findings indicate that variation in compensatory response after CRT could explain the increased HT seen with more intensive chemotherapy, resulting from impaired recovery of hematopoiesis in unirradiated structures. Many imaging modalities have been used to identify regions of functional (active) BM, including 18 F-FDG-PET, 18 F-FLT-PET, and magnetic resonance imaging (MRI) (16,(19)(20)(21)(22)(23)(24)(25). In 1 study, Elicin et al (19) used 18 F-FDG-PET imaging of pelvic BM to identify hematopoietically ABM and found that relatively low doses of radiation were associated with a reduction in SUV, which was correlated Abbreviations: ABM Z active bone marrow; CI Z confidence interval.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy

Noticewala

Williamson

et al. 2017

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

SummaryHematologic toxicity (HT) is a common adverse effect in patients with cervical cancer treated with concurrent chemoradiation therapy. In this study, we used 18 F-fluorodeoxyglucose positron emission tomography to quantify changes in functional bone marrow (BM) in unirradiated (extrapelvic) and irradiated (pelvic) BM in cervical cancer patients treated with concurrent chemotherapy of varying intensities. We found that patients have varying Purpose: To quantify longitudinal changes in active bone marrow (ABM) distributions within unirradiated (extrapelvic) and irradiated (pelvic) bone marrow (BM) in cervical cancer patients treated with concurrent chemoradiation therapy (CRT). Methods and Materials: We sampled 39 cervical cancer patients treated with CRT, of whom 25 were treated with concurrent cisplatin (40 mg/m 2 ) and 14 were treated with cisplatin (40 mg/m 2 ) plus gemcitabine (50-125 mg/m 2 ) (C/G). Patients underwent 18 F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and 1.5 to 6.0 months after treatment. ABM was defined as the subvolume of bone with standardized uptake value (SUV) above the mean SUV of the total bone. The primary aim was to measure the compensatory response, defined as the change in the log of the ratio of extrapelvic versus pelvic ABM percentage from baseline to after treatment. We also quantified the change in the proportion of ABM and mean SUV in pelvic and extrapelvic BM using a 2-sided paired t test. Results: We observed a significant increase in the overall extrapelvic compensatory response after CRT (0.381; 95% confidence interval [CI]: 0.312, 0.449) and separately in patients treated with cisplatin (0.429; 95% CI: 0.340, 0.517) and C/G (0.294; 95% CI: 0.186, 0.402). We observed a trend toward higher compensatory response in patients treated with cisplatin compared with C/G (PZ.057). Pelvic ABM percentage

show abstract

Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning

Cited by 36 publications

References 23 publications

Systematic review of site distribution of bone metastases in differentiated thyroid cancer

Systematic review of site distribution of bone metastases in differentiated thyroid cancer

Dosimetric predictors of treatment-related lymphopenia induced by palliative radiotherapy: predictive ability of dose-volume parameters based on body surface contour

Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy

Contact Info

Product

Resources

About